Related coverage linked through entity extraction aliases.
Jun 24, 2026
A phase 3 trial shows that the oral drug enlicitide reduces LDL cholesterol by 60% compared to placebo, according to results published in the New England Journal of Medicine. Sponsored by Merck & Co., the trial involved 2,909 participants with atherosclerosis or at risk. If approved, enlicitide could help lower heart attack and stroke risk.
Jun 04, 2026
Scientists have developed a new transcriptomic clock that predicts biological age and mortality using gene activity patterns conserved across species. Longevity experts also recommend tracking specific biomarkers like fasting glucose, ApoB, and hs-CRP with optimal ranges to monitor health proactively. Regular biomarker testing from mid-30s onwards is encouraged for early detection of age-related changes.
Mar 29, 2026
Arrowhead Pharmaceuticals presented long-term data showing plozasiran achieved 83% median triglyceride reduction in severe hypertriglyceridemia patients with no acute pancreatitis events over two years. The RNA interference therapy demonstrated durable improvements in atherogenic lipoproteins and consistent safety profile. The company plans to complete Phase 3 studies by mid-2026 and submit for regulatory approval.
Mar 05, 2026
Enlicitide decanoate demonstrated efficacy in reducing LDL cholesterol levels compared to placebo in patients with atherosclerotic cardiovascular disease history or risk, according to phase 3 CORALreef Lipids trial data.
Feb 16, 2026
A phase three clinical trial shows enlicitide, an oral monoclonal antibody, reduced LDL cholesterol by 60% compared to placebo in 2,909 patients with or at risk of atherosclerosis over 24 weeks.
